Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18897019 | Pathogenic Affinity Pathway of Infectious or Parasitic Organisms for Nanogram and Picogram Dosimetry Prophylaxis or Cure | September 2024 | December 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18894811 | THERAPEUTIC METHODS USING BUPROPION HYDROBROMIDE TO TREAT MAJOR DEPRESSIVE DISORDER | September 2024 | March 2025 | Allow | 6 | 1 | 0 | No | No |
| 18739339 | PUERARIA LOBATA NANO-SILVER COMPOSITE HYDROSOL, PREPARATION METHOD AND APPLICATION THEREOF | June 2024 | November 2024 | Allow | 5 | 1 | 0 | No | No |
| 18413304 | Diphenyl Tablets and Methods of Preparing the Same | January 2024 | March 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18541832 | INTRAOPERATIVE TOPICALLY-APPLIED NON-IMPLANTABLE RAPID RELEASE PATCH | December 2023 | February 2025 | Allow | 14 | 2 | 0 | Yes | No |
| 18524738 | LIQUISOFT CAPSULES | November 2023 | January 2025 | Allow | 14 | 1 | 0 | Yes | No |
| 18384042 | PREPARATION METHOD FOR MODIFIED NANO-ZINC OXIDE POWDER | October 2023 | April 2024 | Allow | 5 | 1 | 0 | No | No |
| 18483463 | COMPOSITIONS, SYSTEMS, AND METHODS FOR INCREASED PLANT QUALITY | October 2023 | May 2025 | Allow | 19 | 2 | 1 | Yes | No |
| 18242083 | ENHANCED CURCUMA LONGA PRODUCTIVITY AND MEDICINAL VALUES BY USING MORINGA OLEIFERA LEAF EXTRACT | September 2023 | January 2024 | Allow | 4 | 1 | 0 | No | No |
| 18232120 | PHOTOSTABLE COMPOSITIONS COMPRISING PARA-ALKOXYL PHENYL SUBSTITUTED PROPENOIC ACID (APP) COPOLYMER DERIVATIVES | August 2023 | July 2024 | Allow | 12 | 1 | 0 | No | No |
| 18356932 | N-Oxide and Ectoine Monomers, Polymers, Their Compositions, and Related Methods | July 2023 | December 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18211252 | NANOCOMPOSITE INCLUDING WATER-SOLUBLE NANO-POLYMER AND MESOPOROUS SILICA NANOPARTICLES ENCAPSULATED WITH AZOLE DERIVATIVES | June 2023 | August 2023 | Allow | 2 | 0 | 0 | No | No |
| 18334017 | COMPOSITIONS FOR CONTROLLING ARTHROPODS | June 2023 | September 2024 | Abandon | 15 | 2 | 1 | No | No |
| 18334055 | COMPOSITIONS FOR CONTROLLING ARTHROPODS | June 2023 | September 2024 | Abandon | 15 | 2 | 1 | No | No |
| 18194011 | ANTIVIRAL ARTICLES | March 2023 | August 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18189298 | LIQUID CONCENTRATE FOR PRESERVATION | March 2023 | January 2025 | Allow | 22 | 3 | 0 | Yes | Yes |
| 18174090 | STOVE WITH MOSQUITO REPELLENT COMPONENT | February 2023 | September 2023 | Allow | 7 | 1 | 0 | No | No |
| 18107243 | Solid Pharmaceutical Compositions for Treating HCV | February 2023 | September 2024 | Abandon | 19 | 1 | 0 | No | No |
| 18100225 | Antibacterial Composition and its Use in Treating Bacterial Infections | January 2023 | May 2024 | Allow | 16 | 2 | 0 | Yes | No |
| 18017027 | NITINOL NANOFIBERS | January 2023 | November 2023 | Allow | 9 | 1 | 1 | Yes | No |
| 18153696 | STRESS MANAGEMENT IN LIVESTOCK | January 2023 | February 2025 | Abandon | 25 | 3 | 0 | No | No |
| 18079931 | COMPOSITION FOR OBTAINING A NATURAL BIOACTIVE FOR ONCOLOGIC THERAPIES | December 2022 | April 2025 | Allow | 28 | 0 | 0 | Yes | No |
| 17980684 | BIOMIMETIC NANOFIBER TISSUE SCAFFOLDS | November 2022 | January 2024 | Abandon | 14 | 1 | 0 | No | No |
| 17969266 | PHARMACEUTICAL COMPOSITION FOR IMPROVING HEALTH, CURE ABNORMALITIES AND DEGENERATIVE DISEASE, ACHIEVE ANTI-AGING EFFECT OF THERAPY AND THERAPEUTIC EFFECT ON MAMMALS AND METHOD THEREOF | October 2022 | February 2024 | Allow | 15 | 3 | 0 | No | No |
| 17995905 | FACE MASK, COMPOSITES, IRON-IRON OXIDE COMPOSITIONS AND METHODS OF MANUFACTURE AND USE THEREOF | October 2022 | March 2025 | Allow | 29 | 0 | 0 | Yes | No |
| 17935773 | ANTIMICROBIAL MEDICAL BIOMATERIAL AND A METHOD OF PREPARING THE SAME | September 2022 | August 2023 | Allow | 11 | 1 | 0 | No | No |
| 17944839 | LUBRICATING MEMBER COMPRISING POLYGLUTAMIC ACID | September 2022 | September 2023 | Abandon | 12 | 1 | 0 | Yes | No |
| 17817919 | Oxime Cross-Linked Biocompatible Polymer Hydrogels and Methods of Use Thereof | August 2022 | July 2024 | Abandon | 23 | 2 | 0 | No | No |
| 17797249 | CONTROLLED-RELEASE FORMULATION FOR HEARING LOSS AND PREPARATION METHOD THEREFOR | August 2022 | May 2025 | Allow | 34 | 0 | 1 | Yes | No |
| 17879259 | Microparticle Enabled Delivery Structures, Methods of Preparing and Using Same | August 2022 | June 2025 | Abandon | 35 | 3 | 0 | No | No |
| 17842376 | HYPERBRANCHED POLYGLYCEROL-COATED PARTICLES AND METHODS OF MAKING AND USING THEREOF | June 2022 | October 2023 | Allow | 16 | 1 | 0 | No | No |
| 17837103 | MICRONUTRIENT FORMULATIONS THAT CONTROL PLANT PATHOGENS | June 2022 | March 2024 | Abandon | 21 | 1 | 1 | No | No |
| 17663296 | SURFACES AND COATING COMPOSITIONS HAVING ANTIFOULING, ANTITHROMBOTIC, AND ANTIBACTERIAL PROPERTIES AND METHODS OF MAKING | May 2022 | January 2025 | Allow | 32 | 1 | 1 | Yes | No |
| 17741358 | COMPOSITION AND METHOD FOR CONTROLLED DRUG RELEASE FROM A TISSUE | May 2022 | April 2025 | Abandon | 35 | 4 | 0 | No | No |
| 17727213 | REGENERATIVE BIOACTIVE SUSPENSION DERIVED FROM FRESHLY DISAGGREGATED TISSUE AND METHODS OF USE IN CLINICAL THERAPIES | April 2022 | June 2023 | Abandon | 13 | 2 | 1 | No | No |
| 17768532 | USE OF A FLAVANOID EXTRACT OBTAINED FROM THE SPECIES TALIPARITI ELATUM SW, FORMULATIONS COMPRISING SAME AND TREATMENT METHOD | April 2022 | May 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17704306 | LIQUISOFT CAPSULES | March 2022 | August 2023 | Allow | 17 | 1 | 0 | No | No |
| 17642769 | BIOLOGICAL TISSUE ADHESIVE SHEET, BIOLOGICAL TISSUE REINFORCEMENT MATERIAL KIT, AND METHOD FOR PRODUCING BIOLOGICAL TISSUE ADHESIVE SHEET | March 2022 | November 2024 | Abandon | 32 | 3 | 0 | No | No |
| 17687939 | STAMINA-IMPROVING COMPOSITION AND STAMINA-IMPROVING NATURAL TEA COMPRISING SAME | March 2022 | March 2025 | Allow | 36 | 1 | 0 | Yes | No |
| 17803133 | Topical Skin Treatment | February 2022 | June 2023 | Allow | 15 | 0 | 0 | Yes | No |
| 17677419 | LIGHT-ACTIVATED CHLORINE DIOXIDE-RELEASING POWDER AND METHOD OF MANUFACTURE | February 2022 | February 2024 | Allow | 24 | 2 | 1 | Yes | Yes |
| 17671594 | ANTIBACTERIAL AND ANTIFUNGAL POLYESTER MATERIAL | February 2022 | March 2024 | Allow | 25 | 2 | 0 | Yes | No |
| 17585504 | FORMULATIONS FOR CORNEAL APPLICATION | January 2022 | February 2024 | Abandon | 25 | 4 | 1 | Yes | Yes |
| 17605483 | COMPOSITION COMPRISING ACTINIDIA POLYGAMA EXTRACT FOR ALLEVIATING SKIN DAMAGE OR MOISTURIZING SKIN | January 2022 | February 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17628449 | METHOD FOR EXTRACTION | January 2022 | April 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17597488 | ARTICLES CONTAINING A CROSSLINKED GUANIDINYL-CONTAINING POLYMER AND USES THEREOF | January 2022 | January 2025 | Allow | 36 | 2 | 0 | Yes | Yes |
| 17624851 | MEDICINE FOR TREATING PULMONARY MYCOSIS | January 2022 | April 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17567892 | TryNOVID Boosts Immune System Against Viruses and Variants | January 2022 | August 2024 | Allow | 31 | 0 | 0 | Yes | No |
| 17567599 | COMPOSITIONS AND ARTICLES COMPRISING COMPLEXES OF 1-METHYLCYCLOPROPENE AND ALPHA-CYCLODEXTRIN | January 2022 | February 2024 | Allow | 25 | 2 | 0 | Yes | No |
| 17646655 | HYDROXIDES MONOLAYER NANOPLATELET AND METHODS OF PREPARING SAME | December 2021 | November 2024 | Abandon | 34 | 2 | 1 | Yes | No |
| 17622541 | PHARMACEUTICAL COMPOSITION FOR PREVENTING HAIR LOSS OR PROMOTING HAIR GROWTH, COMPRISING GINSENOSIDE RG4 OR MIXTURE (RGX 365) OF GINSENOSIDES RG2, RG4, RG6, AND RH1 AS ACTIVE INGREDIENT | December 2021 | June 2025 | Allow | 41 | 1 | 1 | No | No |
| 17644745 | COLLOIDAL PARTICLE FORMULATIONS WITH ADVANCED FUNCTIONALITY | December 2021 | August 2023 | Allow | 20 | 2 | 1 | Yes | No |
| 17618013 | PLANT EXTRACT MIXTURE FOR USE IN THE PREVENTION AND/OR TREATMENT OF CHRONIC INFLAMMATORY BOWEL DISEASES | December 2021 | January 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17551719 | INSECT CONTROL PRODUCT FOR ANIMALS | December 2021 | September 2024 | Abandon | 33 | 2 | 0 | No | No |
| 17548976 | Use Of A Composition For The Pigmentation Of Hair And Hairs | December 2021 | May 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17617009 | AN ANTIMICROBIAL COATING COMPOSITION | December 2021 | February 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17534667 | METHOD OF TREATING OR AMELIORATING SKIN CONDITIONS WITH A MAGNETIC DIPOLE STABILIZED SOLUTION | November 2021 | August 2023 | Abandon | 21 | 1 | 0 | No | No |
| 17453101 | METHODS AND COMPOSITIONS FOR TREATING HYPERHIDROSIS | November 2021 | June 2023 | Allow | 19 | 1 | 0 | No | No |
| 17506967 | PHARMACEUTICAL COMPOSITION COMPRISING EXTRACT FROM CAMELLIA JAPONICA AS ACTIVE INGREDIENT FOR PREVENTION AND TREATMENT OF VIRAL INFECTION | October 2021 | December 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17417992 | COMPOSITION FOR PREVENTING OR TREATING SKIN DISEASES COMPRISING BRIDALWREATH SPIREA | October 2021 | May 2025 | Abandon | 46 | 2 | 0 | No | No |
| 17600910 | VARIOUS USES OF THE NANOPARTICULATE COMPOUND OF TITANIUM DIOXIDE FUNCTIONALIZED | October 2021 | April 2024 | Abandon | 30 | 2 | 0 | No | No |
| 17600793 | SYNERGISTIC HERBAL COMPOSITIONS FOR PREVENTION, TREATMENT OR CONTROL OF PAIN AND/OR CARTILAGE REGENERATION | October 2021 | June 2025 | Abandon | 45 | 2 | 1 | Yes | No |
| 17599844 | AGENT FOR CONTROLLING PESTS SUCH AS RODENTS | September 2021 | November 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17442483 | METHODS FOR CONTINUOUS EXTRACTION AND PURIFICATION OF A UNIQUE FLAVAN-3-OL EXTRACT FROM IMMATURE WHOLE GRAPE CLUSTERS AND COMPOSITIONS THEREOF | September 2021 | November 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17593444 | FREEZE-DRIED FORMULATION, PREPARATION METHOD AND APPLICATION THEREOF | September 2021 | June 2025 | Abandon | 45 | 2 | 1 | No | No |
| 17439169 | AQUEOUS AGROCHEMICAL SUSPENSION COMPOSITION AND METHOD FOR SPRAYING SAME | September 2021 | December 2022 | Allow | 15 | 2 | 0 | Yes | No |
| 17462316 | BIOMIMETIC NANOFIBER TISSUE SCAFFOLDS | August 2021 | August 2022 | Allow | 12 | 1 | 1 | No | No |
| 17461667 | BIOMIMETIC NANOFIBER TISSUE SCAFFOLDS | August 2021 | August 2022 | Allow | 12 | 1 | 1 | No | No |
| 17433805 | MAQUI BERRY EXTRACTS FOR USE IN THE TREATMENT OR PREVENTION OF BONE DISORDERS | August 2021 | March 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17403097 | ANTIVIRAL METAL TREATMENTS FOR FIBER SUBSTRATES, FILTER MEDIA HAVING ANTIVIRAL METAL TREATMENTS, AND PROCESSES FOR TREATING FIBER SUBSTRATES | August 2021 | October 2024 | Abandon | 38 | 4 | 0 | Yes | No |
| 17392833 | Antiviral Antimicrobial Article | August 2021 | January 2024 | Abandon | 29 | 3 | 1 | Yes | Yes |
| 17384480 | Photostable Compositions Comprising Para-Alkoxyl Phenyl Substituted Propenoic Acid (APP) Copolymer Derivatives | July 2021 | May 2023 | Allow | 21 | 1 | 0 | No | No |
| 17364968 | SKIN CARE FORMULATION | July 2021 | May 2023 | Abandon | 22 | 1 | 0 | No | No |
| 17365055 | COMPOSITION FOR THE TREATMENT AND/OR PREVENTION OF LOWER URINARY TRACT SYMPTOMS | July 2021 | June 2024 | Allow | 35 | 1 | 0 | No | No |
| 17304890 | SPATIOTEMPORAL DELIVERY SYSTEM EMBEDDED IN 3D-PRINTING | June 2021 | May 2024 | Abandon | 34 | 2 | 0 | No | No |
| 17304689 | COLOR INK SET FOR COSMETIC APPLICATION | June 2021 | August 2023 | Abandon | 26 | 2 | 0 | Yes | No |
| 17415368 | METHOD FOR PREPARING A BIOCIDAL, BACTERIOCIDAL AND/OR BACTERIOSTATIC MATERIAL | June 2021 | October 2024 | Allow | 40 | 1 | 1 | Yes | No |
| 17348026 | PESTICIDE-CONTAINING SOIL DISINFESTATION MATERIAL WITHOUT USE OF FUMIGANT | June 2021 | February 2024 | Allow | 32 | 4 | 0 | No | No |
| 17413714 | CERIUM OXIDE NANOPARTICLE, DECOMPOSITION METHOD OF NUCLEIC ACID, DECOMPOSITION METHOD OF POLYPEPTIDE, METHOD OF PRODUCING CERIUM OXIDE NANOPARTICLE, OXIDIZING AGENT, ANTIOXIDANT, ANTIFUNGAL AGENT, AND ANTI-VIRUS AGENT | June 2021 | December 2023 | Allow | 30 | 3 | 0 | Yes | No |
| 17347267 | ANTIMICROBIAL ARTICLE AND MANUFACTURING METHOD THEREOF | June 2021 | July 2023 | Abandon | 25 | 1 | 1 | No | No |
| 17326948 | ANTIMICROBIAL/ANTIVIRAL NONWOVEN AND APPLICATIONS OF THE SAME | May 2021 | July 2023 | Abandon | 26 | 2 | 0 | No | No |
| 17295679 | COMPOSITION FOR USE IN THE PREVENTION AND/OR SYMPTOMATIC TREATMENT OF IRRITABLE BOWEL SYNDROME | May 2021 | September 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17317937 | ANTIBACTERIAL COATING MATERIAL, METHOD OF MANUFACTURING AN ANTIBACTERIAL COATING MATERIAL, ANTIBACTERIAL COATING LAYER AND ANTIVIRAL ADHESIVE TAPE | May 2021 | February 2023 | Abandon | 21 | 0 | 1 | No | No |
| 17244908 | BIOMIMETIC NANOFIBER TISSUE SCAFFOLDS | April 2021 | August 2021 | Allow | 3 | 0 | 1 | Yes | No |
| 17243524 | SYSTEM AND METHOD FOR IMPREGNATING A POROUS SURFACE WITH ANTIBACTERIAL AND ANTIVIRAL COMPOUNDS | April 2021 | August 2024 | Allow | 40 | 3 | 1 | Yes | No |
| 17235827 | COATING FOR CAPTURING AND KILLING VIRUSES ON SURFACES | April 2021 | September 2022 | Allow | 16 | 0 | 1 | Yes | No |
| 17286611 | WITHANIA SOMNIFERA COMPOSITION, METHOD OF PREPARATION AND USE THEREOF | April 2021 | July 2024 | Allow | 39 | 1 | 0 | Yes | No |
| 17232808 | POLYMERIC MICELLES CONTAINING AN ESSENTIAL OIL COMPOUND AND A METHOD OF MAKING SAME | April 2021 | September 2024 | Abandon | 41 | 3 | 1 | Yes | No |
| 17228251 | ANTIBIOTIC-FREE ANTIMICROBIAL FEED ADDITIVES AND ANTIMICROBIAL COMPOSITIONS | April 2021 | June 2024 | Abandon | 39 | 4 | 1 | No | No |
| 17227326 | ANTIVIRAL FIBERS, FABRICS AND FABRIC-BASED PRODUCTS | April 2021 | June 2023 | Abandon | 27 | 2 | 0 | No | No |
| 17280975 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES, CONTAINING ANGELICA GIGAS NAKAI EXTRACT OR MIXED EXTRACT OF ANGELICA GIGAS NAKAI AND BROCCOLI | March 2021 | January 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17213521 | COUGH PATCH WITH GERMICIDAL AND/OR ANTIMICROBIAL PROPERTIES | March 2021 | February 2023 | Abandon | 23 | 1 | 0 | No | No |
| 17206496 | COPPER MICROBE STOPPER | March 2021 | December 2024 | Allow | 45 | 4 | 1 | Yes | No |
| 17275264 | COMPOSITIONS COMPRISING CBD FOR TREATING DERMATOLOGICAL CONDITIONS | March 2021 | July 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17192533 | ANTIVIRAL ARTICLES | March 2021 | December 2022 | Allow | 22 | 2 | 0 | No | No |
| 17269231 | TISSUE ENGINEERING BONE SCAFFOLD AND PREPARATION METHOD THEREOF | February 2021 | September 2022 | Abandon | 19 | 1 | 0 | No | No |
| 17170013 | ANTIMICROBIAL MEDICAL BIOMATERIAL AND A METHOD FOR PREPARING THE SAME | February 2021 | April 2023 | Allow | 26 | 1 | 1 | No | No |
| 17260850 | COMPLEX OXIDE CERAMIC, METHOD FOR PRODUCING SAME, AND ARTICLE | January 2021 | September 2023 | Allow | 32 | 2 | 0 | No | No |
| 17247808 | COLLOIDAL PARTICLE FORMULATIONS WITH ADVANCED FUNCTIONALITY | December 2020 | March 2025 | Allow | 50 | 8 | 1 | Yes | No |
| 17255770 | SUBSTITUTED 2-HETEROARYLOXYPYRIDINES AND SALTS THEREOF AND THEIR USE AS HERBICIDAL AGENTS | December 2020 | July 2023 | Allow | 31 | 0 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PURDY, KYLE A.
With a 22.6% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 17.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner PURDY, KYLE A works in Art Unit 1611 and has examined 963 patent applications in our dataset. With an allowance rate of 41.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.
Examiner PURDY, KYLE A's allowance rate of 41.6% places them in the 4% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by PURDY, KYLE A receive 2.87 office actions before reaching final disposition. This places the examiner in the 93% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by PURDY, KYLE A is 39 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +39.9% benefit to allowance rate for applications examined by PURDY, KYLE A. This interview benefit is in the 89% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 10.0% of applications are subsequently allowed. This success rate is in the 2% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 23.5% of cases where such amendments are filed. This entry rate is in the 23% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 44.4% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 37% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 57.3% of appeals filed. This is in the 25% percentile among all examiners. Of these withdrawals, 38.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 78.1% are granted (fully or in part). This grant rate is in the 91% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 4.0% of allowed cases (in the 87% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.0% of allowed cases (in the 65% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.